Home » Newsletters » BioWorld Science

BioWorld Science

April 6, 2006

View Archived Issues

Preclinical and clinical investigation of SNS-595 in cancer advances

Ambit Biosciences presents new FLT-3 inhibitor for AML

Wyeth presents novel class of selective cPLA2alpha inhibitors for inflammation

IND cleared for phase I study of D93

Orphan drug designation for EPI-A0001

Epix and Predix sign merger agreement

Geron studies GRN-163L in patients with solid tumor malignancies

Phase III breast cancer trial of Tykerb with capecitabine exceeds primary endpoint

Novel 5-HT6 antagonists from Korean Research Institute of Chemical Technology

New orally active progesterone receptor agonists presented by Wyeth

U.S. subsidiaries form new Daiichi Sankyo

Astellas to acquire worldwide rights to Amevive

FDA completes IND review for Oncaspar in NHL and solid tumors

Trials of CX-717 placed on clinical hold

Incyte discontinues development of DFC

Initial preclinical data for ReN-003 retinal stem cell therapy program

Dainippon Sumitomo merges U.S. subsidiaries

Orphan drug designation for lestaurtinib in AML

Veronate fails to meet phase III study endpoints

Celebrex reduces precancerous polyps in high-risk patients

PTC-124 shows pharmacological activity in CF patients with nonsense mutation

Novel antiinfective agents reported in recent patent literature

Novel p38alpha MAPK inhibitors emerge from Pfizer R&D

Novel agents for respiratory disorders disclosed in recent patents

Taclonex now available in U.S.

Pyridopyridazines with potent and selective dual PI3-kinase/ERK2-inhibitory activity

Second approvable letter for Surfaxin

Antitumor activity of RGB-286638, a potent, broad-spectrum CDK inhibitor

Oncogenic B-Raf inhibitor advanced as first oncology candidate at Plexxikon

Antitumor activity of potent multiple-kinase inhibitor further characterized

Novel inhibitors of hepatitis C virus replicon system identified

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...